Lucid Common Stock Shares Outstanding from 2010 to 2026
| LUCD Stock | USD 1.16 0.06 4.92% |
Common Stock Shares Outstanding | First Reported 2018-12-31 | Previous Quarter 99 M | Current Value 108.2 M | Quarterly Volatility 19 M |
Check Lucid Diagnostics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lucid Diagnostics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 997.8 K, Interest Expense of 28.4 K or Selling General Administrative of 24.3 B, as well as many indicators such as Price To Sales Ratio of 10.4, Dividend Yield of 0.0 or PTB Ratio of 7.25. Lucid financial statements analysis is a perfect complement when working with Lucid Diagnostics Valuation or Volatility modules.
Lucid | Common Stock Shares Outstanding | Build AI portfolio with Lucid Stock |
Latest Lucid Diagnostics' Common Stock Shares Outstanding Growth Pattern
Below is the plot of the Common Stock Shares Outstanding of Lucid Diagnostics over the last few years. It is the total number of shares of a company's common stock that are currently owned by all its shareholders. Lucid Diagnostics' Common Stock Shares Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lucid Diagnostics' overall financial position and show how it may be relating to other accounts over time.
| Common Stock Shares Outstanding | 10 Years Trend |
|
Common Stock Shares Outstanding |
| Timeline |
Lucid Common Stock Shares Outstanding Regression Statistics
| Arithmetic Mean | 39,576,248 | |
| Geometric Mean | 39,217,771 | |
| Coefficient Of Variation | 15.19 | |
| Mean Deviation | 4,158,792 | |
| Median | 36,992,000 | |
| Standard Deviation | 6,013,181 | |
| Sample Variance | 36.2T | |
| Range | 22M | |
| R-Value | 0.61 | |
| Mean Square Error | 24.2T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | 727,865 | |
| Total Sum of Squares | 578.5T |
Lucid Common Stock Shares Outstanding History
About Lucid Diagnostics Financial Statements
Lucid Diagnostics stakeholders use historical fundamental indicators, such as Lucid Diagnostics' Common Stock Shares Outstanding, to determine how well the company is positioned to perform in the future. Although Lucid Diagnostics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lucid Diagnostics' assets and liabilities are reflected in the revenues and expenses on Lucid Diagnostics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lucid Diagnostics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 58.1 M | 43.3 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out the analysis of Lucid Diagnostics Correlation against competitors. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Will Health Care Equipment & Supplies sector continue expanding? Could Lucid diversify its offerings? Factors like these will boost the valuation of Lucid Diagnostics. Expected growth trajectory for Lucid significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lucid Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
Understanding Lucid Diagnostics requires distinguishing between market price and book value, where the latter reflects Lucid's accounting equity. The concept of intrinsic value—what Lucid Diagnostics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lucid Diagnostics' price substantially above or below its fundamental value.
Understanding that Lucid Diagnostics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lucid Diagnostics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lucid Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.